{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:29:02Z","timestamp":1787020142250,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T00:00:00Z","timestamp":1729296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T00:00:00Z","timestamp":1729296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-024-03812-7","type":"journal-article","created":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T15:01:46Z","timestamp":1729350106000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Renal involvement in solid cancers: epidemiological, clinical and histological characteristics study of 154 onconephrology patients"],"prefix":"10.1186","volume":"25","author":[{"given":"Victor","family":"Gueutin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Cardineau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Mathian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Lanot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Comoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Brocheriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Izzedine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,19]]},"reference":[{"key":"3812_CR1","doi-asserted-by":"publisher","unstructured":"Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer [Internet]. 4 juin 2021 [cit\u00e9 12 juill 2021];cncr.33587. Disponible sur: https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1002\/cncr.33587","DOI":"10.1002\/cncr.33587"},{"key":"3812_CR2","unstructured":"Wild CP, Weiderpass E, Stewart BW. World Cancer Report: Cancer Research for Cancer Prevention. Lyon, France: International Agency for Research on Cancer. [Internet]. 2020. Disponible sur: http:\/\/publications.iarc.fr\/586. Licence: CC BY-NC-ND 3.0 IGO."},{"key":"3812_CR3","doi-asserted-by":"publisher","unstructured":"Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. Impact of comorbidity on lung cancer survival. Int J Cancer [Internet]. 1 mars 2003 [cit\u00e9 29 sept 2022];103(6):792\u2013802. Disponible sur: https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1002\/ijc.10882","DOI":"10.1002\/ijc.10882"},{"key":"3812_CR4","doi-asserted-by":"crossref","unstructured":"Lee JC. The Association of Cancer and the Nephrotic Syndrome. Ann Intern Med [Internet]. 1 janv 1966 [cit\u00e9 24 juill 2021];64(1):41. Disponible sur: http:\/\/annals.org\/article.aspx?doi=10.7326\/0003-4819-64-1-41","DOI":"10.7326\/0003-4819-64-1-41"},{"key":"3812_CR5","doi-asserted-by":"crossref","unstructured":"Birkeland SA, Storm HH. Glomerulonephritis and malignancy: a population-based analysis. Kidney international [Internet]. f\u00e9vr 2003 [cit\u00e9 13 juill 2021];63(2):716\u201321. Disponible sur: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815489276","DOI":"10.1046\/j.1523-1755.2003.00771.x"},{"key":"3812_CR6","doi-asserted-by":"publisher","unstructured":"Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP et al. Elevations of inflammatory and procoagulant biomarkers in Elderly persons with renal insufficiency. Circulation [Internet]. 7 janv 2003 [cit\u00e9 12 juill 2021];107(1):87\u201392. Disponible sur: https:\/\/www.ahajournals.org\/doi\/https:\/\/doi.org\/10.1161\/01.CIR.0000042700.48769.59","DOI":"10.1161\/01.CIR.0000042700.48769.59"},{"key":"3812_CR7","doi-asserted-by":"publisher","unstructured":"Kleber M, Ihorst G, Deschler B, Jakob C, Liebisch P, Koch B et al. Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients. European Journal of Haematology [Internet]. d\u00e9c 2009 [cit\u00e9 29 sept 2022];83(6):519\u201327. Disponible sur: https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1111\/j.1600-0609.2009.01318.x","DOI":"10.1111\/j.1600-0609.2009.01318.x"},{"key":"3812_CR8","doi-asserted-by":"publisher","unstructured":"J\u00f8rgensen L, Heuch I, Jenssen T, Jacobsen BK. Association of Albuminuria and Cancer incidence. JASN [Internet]. Mai 2008 [cit\u00e9 12 juill 2021];19(5):992\u20138. Disponible sur: https:\/\/jasn.asnjournals.org\/lookup\/doi\/https:\/\/doi.org\/10.1681\/ASN.2007060712","DOI":"10.1681\/ASN.2007060712"},{"key":"3812_CR9","doi-asserted-by":"publisher","unstructured":"Lowrance WT, Ordo\u00f1ez J, Udaltsova N, Russo P, Go AS. CKD and the risk of Incident Cancer. JASN [Internet]. Oct 2014 [cit\u00e9 12 juill 2021];25(10):2327\u201334. Disponible sur: https:\/\/jasn.asnjournals.org\/lookup\/doi\/https:\/\/doi.org\/10.1681\/ASN.2013060604","DOI":"10.1681\/ASN.2013060604"},{"key":"3812_CR10","doi-asserted-by":"crossref","unstructured":"Malyszko J, Tesarova P, Capasso G, Capasso A. The link between kidney disease and cancer: complications and treatment. The Lancet [Internet]. Juill 2020 [cit\u00e9 12 juill 2021];396(10246):277\u201387. Disponible sur: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673620305407","DOI":"10.1016\/S0140-6736(20)30540-7"},{"key":"3812_CR11","doi-asserted-by":"publisher","unstructured":"Cambier JF, Ronco P, Onco-Nephrology. Glomerular diseases with Cancer. CJASN [Internet]. Oct 2012 [cit\u00e9 25 juill 2021];7(10):1701\u201312. Disponible sur: https:\/\/cjasn.asnjournals.org\/lookup\/doi\/https:\/\/doi.org\/10.2215\/CJN.03770412","DOI":"10.2215\/CJN.03770412"},{"key":"3812_CR12","doi-asserted-by":"crossref","unstructured":"Bacchetta J, Juillard L, Cochat P, Droz JP. Paraneoplastic glomerular diseases and malignancies. Critical Reviews in Oncology\/Hematology [Internet]. avr 2009 [cit\u00e9 13 juill 2021];70(1):39\u201358. Disponible sur: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842808001789","DOI":"10.1016\/j.critrevonc.2008.08.003"},{"key":"3812_CR13","doi-asserted-by":"crossref","unstructured":"Cosmai L, Porta C, Privitera C, Gesualdo L, Procopio G, Gori S et al. Acute kidney injury from contrast-enhanced CT procedures in patients with cancer: white paper to highlight its clinical relevance and discuss applicable preventive strategies. ESMO Open [Internet]. 2020 [cit\u00e9 18 sept 2021];5(2):e000618. Disponible sur: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702920300521","DOI":"10.1136\/esmoopen-2019-000618"},{"key":"3812_CR14","doi-asserted-by":"crossref","unstructured":"Perazella MA, Izzedine H. New drug toxicities in the onco-nephrology world. Kidney International [Internet]. mai 2015 [cit\u00e9 12 sept 2021];87(5):909\u201317. Disponible sur: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815300806","DOI":"10.1038\/ki.2015.30"},{"key":"3812_CR15","doi-asserted-by":"publisher","unstructured":"Ma\u0142yszko J, Koz\u0142owska K, Koz\u0142owski L, Ma\u0142yszko J. Nephrotoxicity of anticancer treatment. Nephrol Dial Transplant [Internet]. 5 oct 2016 [cit\u00e9 12 juill 2021];gfw338. Disponible sur: http:\/\/ndt.oxfordjournals.org\/lookup\/doi\/https:\/\/doi.org\/10.1093\/ndt\/gfw338","DOI":"10.1093\/ndt\/gfw338"},{"key":"3812_CR16","doi-asserted-by":"publisher","unstructured":"Izzedine H, Perazella MA. Onco-nephrology: an appraisal of the cancer and chronic kidney disease links. Nephrol Dial Transplant [Internet]. d\u00e9c 2015 [cit\u00e9 20 sept 2022];30(12):1979\u201388. Disponible sur: https:\/\/academic.oup.com\/ndt\/article-lookup\/doi\/https:\/\/doi.org\/10.1093\/ndt\/gfu387","DOI":"10.1093\/ndt\/gfu387"},{"key":"3812_CR17","doi-asserted-by":"crossref","unstructured":"Cosmai L, Porta C, Perazella MA, Launay-Vacher V, Rosner MH, Jhaveri KD et al. Opening an onconephrology clinic: recommendations and basic requirements. Nephrology Dialysis Transplantation [Internet]. 1 sept 2018 [cit\u00e9 20 sept 2022];33(9):1503\u201310. Disponible sur: https:\/\/academic.oup.com\/ndt\/article\/33\/9\/1503\/5049712","DOI":"10.1093\/ndt\/gfy188"},{"key":"3812_CR18","doi-asserted-by":"publisher","unstructured":"Soares M, Salluh JIF, Carvalho MS, Darmon M, Rocco JR, Spector N. Prognosis of critically ill patients with Cancer and Acute Renal Dysfunction. JCO [Internet]. 20 ao\u00fbt 2006 [cit\u00e9 12 juill 2021];24(24):4003\u201310. Disponible sur: https:\/\/doi.org\/10.1200\/JCO.2006.05.7869","DOI":"10.1200\/JCO.2006.05.7869"},{"key":"3812_CR19","doi-asserted-by":"crossref","unstructured":"Chang FC, Chen TWW, Huang TTM, Lin WC, Liu JS, Chiang WC et al. Spectrum of cancer patients receiving renal biopsy. Journal of the Formosan Medical Association [Internet]. janv 2022 [cit\u00e9 19 juin 2022];121(1):152\u201361. Disponible sur: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664621000735","DOI":"10.1016\/j.jfma.2021.02.009"},{"key":"3812_CR20","unstructured":"KDIGO. 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease."},{"issue":"4S","key":"3812_CR21","first-page":"S117","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the evaluation and management of chronic kidney disease. Kidney Int avr. 2024;105(4S):S117\u2013314.","journal-title":"Kidney Int avr"},{"key":"3812_CR22","doi-asserted-by":"crossref","unstructured":"Lameire NH, Levin A, Kellum JA, Cheung M, Jadoul M, Winkelmayer WC et al. sept. Harmonizing acute and chronic kidney disease definition and classification: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney Int. 2021;100(3):516\u201326.","DOI":"10.1016\/j.kint.2021.06.028"},{"key":"3812_CR23","doi-asserted-by":"publisher","unstructured":"Perazella MA. Pharmacology behind Common Drug Nephrotoxicities. CJASN [Internet]. 7 d\u00e9c 2018 [cit\u00e9 6 ao\u00fbt 2021];13(12):1897\u2013908. Disponible sur: https:\/\/cjasn.asnjournals.org\/lookup\/doi\/https:\/\/doi.org\/10.2215\/CJN.00150118","DOI":"10.2215\/CJN.00150118"},{"key":"3812_CR24","doi-asserted-by":"publisher","unstructured":"Latcha S, Jaimes EA, Patil S, Glezerman IG, Mehta S, Flombaum CD. Long\u2013Term Renal Outcomes after Cisplatin Treatment. CJASN [Internet]. 7 juill 2016 [cit\u00e9 24 sept 2021];11(7):1173\u20139. Disponible sur: https:\/\/cjasn.asnjournals.org\/lookup\/doi\/https:\/\/doi.org\/10.2215\/CJN.08070715","DOI":"10.2215\/CJN.08070715"},{"key":"3812_CR25","doi-asserted-by":"crossref","unstructured":"Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney international [Internet]. Mai 2008 [cit\u00e9 24 oct 2021];73(9):994\u20131007. Disponible sur: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815531244","DOI":"10.1038\/sj.ki.5002786"},{"issue":"4","key":"3812_CR26","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/annonc\/mdv623","volume":"27","author":"S Champiat","year":"2016","unstructured":"Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Annals Oncol [Internet] avr. 2016;27(4):559\u201374. Disponible sur:. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419357503.","journal-title":"Annals Oncol [Internet] avr"},{"key":"3812_CR27","doi-asserted-by":"crossref","unstructured":"Izzedine H, Gueutin V. Toxicit\u00e9s r\u00e9nales des inhibiteurs des points de contr\u00f4le de l\u2019auto-immunit\u00e9. N\u00e9phrologie & Th\u00e9rapeutique [Internet]. f\u00e9vr 2020 [cit\u00e9 13 sept 2021];16(1):19\u201326. Disponible sur: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725519305280","DOI":"10.1016\/j.nephro.2019.05.006"},{"issue":"2","key":"3812_CR28","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000455014","volume":"45","author":"R Wanchoo","year":"2017","unstructured":"Wanchoo R, Karam S, Uppal NN, Barta VS, Deray G, Devoe C, et al. Adverse renal effects of Immune Checkpoint inhibitors: a narrative review. Am J Nephrol [Internet]. 2017;45(2):160\u20139. Disponible sur:. https:\/\/www.karger.com\/Article\/FullText\/455014. [cit\u00e9 20 sept 2022];.","journal-title":"Am J Nephrol [Internet]"},{"key":"3812_CR29","doi-asserted-by":"crossref","unstructured":"Sury K, Perazella MA, Shirali AC. Cardiorenal complications of immune checkpoint inhibitors. Nat Rev Nephrol [Internet]. sept 2018 [cit\u00e9 13 oct 2021];14(9):571\u201388. Disponible sur: http:\/\/www.nature.com\/articles\/s41581-018-0035-1","DOI":"10.1038\/s41581-018-0035-1"},{"key":"3812_CR30","doi-asserted-by":"publisher","unstructured":"Manohar S, Leung N. Cisplatin nephrotoxicity: a review of the literature. J Nephrol [Internet]. f\u00e9vr 2018 [cit\u00e9 29 ao\u00fbt 2021];31(1):15\u201325. Disponible sur: http:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/s40620-017-0392-z","DOI":"10.1007\/s40620-017-0392-z"},{"key":"3812_CR31","doi-asserted-by":"crossref","unstructured":"Izzedine H, Escudier B, Lhomme C, Pautier P, Rouvier P, Gueutin V et al. Kidney diseases Associated with Anti-vascular endothelial growth factor (VEGF): an 8-year Observational Study at a single Center. Medicine [Internet]. Nov 2014 [cit\u00e9 7 ao\u00fbt 2021];93(24):333\u20139. Disponible sur: https:\/\/journals.lww.com\/00005792-201411040-00002","DOI":"10.1097\/MD.0000000000000207"},{"key":"3812_CR32","doi-asserted-by":"crossref","unstructured":"Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC. VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. European Journal of Cancer [Internet]. Janv 2010 [cit\u00e9 29 sept 2022];46(2):439\u201348. Disponible sur: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804909008387","DOI":"10.1016\/j.ejca.2009.11.001"},{"issue":"1","key":"3812_CR33","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1159\/000365156","volume":"40","author":"RA Lafayette","year":"2014","unstructured":"Lafayette RA, McCall B, Li N, Chu L, Werner P, Das A, et al. Incidence and relevance of Proteinuria in Bevacizumab-Treated patients: pooled analysis from Randomized controlled trials. Am J Nephrol [Internet]. 2014;40(1):75\u201383. Disponible sur:. https:\/\/www.karger.com\/Article\/FullText\/365156.","journal-title":"Am J Nephrol [Internet]"},{"key":"3812_CR34","doi-asserted-by":"publisher","unstructured":"Abbas A, Mirza MM, Ganti AK, Tendulkar K. Renal Toxicities of Targeted Therapies. Targ Oncol [Internet]. d\u00e9c 2015 [cit\u00e9 29 sept 2022];10(4):487\u201399. Disponible sur: http:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/s11523-015-0368-7","DOI":"10.1007\/s11523-015-0368-7"},{"key":"3812_CR35","doi-asserted-by":"crossref","unstructured":"Person F, Rinschen MM, Brix SR, Wulf S, Noriega M, de las M, Fehrle W et al. Bevacizumab-associated glomerular microangiopathy. Mod pathol [Internet]. Mai 2019 [cit\u00e9 29 sept 2022];32(5):684\u2013700. Disponible sur: http:\/\/www.nature.com\/articles\/s41379-018-0186-4","DOI":"10.1038\/s41379-018-0186-4"},{"key":"3812_CR36","doi-asserted-by":"crossref","unstructured":"Keir LS, Firth R, Aponik L, Feitelberg D, Sakimoto S, Aguilar E et al. VEGF regulates local inhibitory complement proteins in the eye and kidney. Journal of Clinical Investigation [Internet]. 5 d\u00e9c 2016 [cit\u00e9 29 sept 2022];127(1):199\u2013214. Disponible sur: https:\/\/www.jci.org\/articles\/view\/86418","DOI":"10.1172\/JCI86418"},{"issue":"10","key":"3812_CR37","doi-asserted-by":"publisher","first-page":"e003467","DOI":"10.1136\/jitc-2021-003467","volume":"9","author":"S Gupta","year":"2021","unstructured":"Gupta S, Short SAP, Sise ME, Prosek JM, Madhavan SM, Soler MJ, et al. Acute kidney injury in patients treated with immune checkpoint inhibitors. J Immunother Cancer oct. 2021;9(10):e003467.","journal-title":"J Immunother Cancer oct"},{"key":"3812_CR38","doi-asserted-by":"crossref","unstructured":"Belliere J, Mazieres J, Meyer N, Chebane L, Despas F. Renal Complications Related to Checkpoint Inhibitors: Diagnostic and Therapeutic Strategies. Diagnostics. 30 juin. 2021;11(7):1187.","DOI":"10.3390\/diagnostics11071187"},{"key":"3812_CR39","doi-asserted-by":"publisher","unstructured":"Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer [Internet]. 15 sept 2007 [cit\u00e9 24 sept 2021];110(6):1376\u201384. Disponible sur: https:\/\/doi.org\/10.1002\/cncr.22904","DOI":"10.1002\/cncr.22904"},{"issue":"1","key":"3812_CR40","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1053\/j.ajkd.2013.07.008","volume":"63","author":"S Iff","year":"2014","unstructured":"Iff S, Craig JC, Turner R, Chapman JR, Wang JJ, Mitchell P, et al. Reduced estimated GFR and cancer mortality. Am J Kidney Dis janv. 2014;63(1):23\u201330.","journal-title":"Am J Kidney Dis janv"},{"issue":"5","key":"3812_CR41","first-page":"CR209","volume":"10","author":"V Launay-Vacher","year":"2004","unstructured":"Launay-Vacher V, Izzedine H, Rey JB, Rixe O, Chapalain S, Nourdine S, et al. Incidence of renal insufficiency in cancer patients and evaluation of information available on the use of anticancer drugs in renally impaired patients. Med Sci Monit Mai. 2004;10(5):CR209\u2013212.","journal-title":"Med Sci Monit Mai"},{"key":"3812_CR42","doi-asserted-by":"publisher","unstructured":"Casal MA, Nolin TD, Beumer JH. Estimation of Kidney Function in Oncology: Implications for Anticancer Drug Selection and Dosing. CJASN [Internet]. 5 avr 2019 [cit\u00e9 29 sept 2022];14(4):587\u201395. Disponible sur: https:\/\/cjasn.asnjournals.org\/lookup\/doi\/https:\/\/doi.org\/10.2215\/CJN.11721018","DOI":"10.2215\/CJN.11721018"},{"key":"3812_CR43","doi-asserted-by":"crossref","unstructured":"Launay-Vacher V, Chatelut E, Lichtman SM, Wildiers H, Steer C, Aapro M. Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Annals of Oncology [Internet]. ao\u00fbt 2007 [cit\u00e9 29 sept 2022];18(8):1314\u201321. Disponible sur: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419428937","DOI":"10.1093\/annonc\/mdm011"},{"issue":"8","key":"3812_CR44","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.2215\/CJN.0000000000000508","volume":"19","author":"A Kitchlu","year":"2024","unstructured":"Kitchlu A, Silva VTCE, Anand S, Kala J, Abudayyeh A, Inker LA, et al. Assessment of GFR in patients with Cancer: A Statement from the American Society of Onco-Nephrology. Clin J Am Soc Nephrol 1 ao\u00fbt. 2024;19(8):1061\u201372.","journal-title":"Clin J Am Soc Nephrol 1 ao\u00fbt"},{"issue":"3","key":"3812_CR45","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.kint.2021.12.010","volume":"101","author":"E Costa","year":"2022","unstructured":"Costa E, Silva VT, Gil LA, Inker LA, Caires RA, Costalonga E, Coura-Filho G, et al. A prospective cross-sectional study estimated glomerular filtration rate from creatinine and cystatin C in adults with solid tumors. Kidney Int mars. 2022;101(3):607\u201314.","journal-title":"Kidney Int mars"},{"key":"3812_CR46","doi-asserted-by":"publisher","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM et al. Management of Immune-related adverse events in patients treated with Immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. JCO [Internet]. 10 juin 2018 [cit\u00e9 30 sept 2021];36(17):1714\u201368. Disponible sur: https:\/\/doi.org\/10.1200\/JCO.2017.77.6385","DOI":"10.1200\/JCO.2017.77.6385"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-024-03812-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-024-03812-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-024-03812-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T15:02:19Z","timestamp":1729350139000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-024-03812-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,19]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3812"],"URL":"https:\/\/doi.org\/10.1186\/s12882-024-03812-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4667296\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,19]]},"assertion":[{"value":"1 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Local Ethics Committee of Caen University Hospital (ref: 3155 bis\/2022) in accordance with the declaration of Helsinki and health data processing in compliance with the European regulation of April 27, 2016 on the protection of individuals with regard to the processing of personal data. No consent was required for this retrospective study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"367"}}